Lupin Q2 FY27 Earnings Call | 4 Nov 2026

Описание: Lupin Q2 FY27 earnings call, held on 4 November 2026. The full analyst Q&A session, with the investor presentation on screen when the company filed one.

🔔 SUBSCRIBE to Concall Central and turn on notifications. Every Indian concall, the day it happens. Never miss one. Results, guidance and the management commentary that moves stocks, in one place.

📌 7 key takeaways from the Lupin Q2 FY27 concall
1. Total revenue reached Rs 7,827 crore in Q2 FY27, representing an 11% year-on-year increase despite a quarter-on-quarter decline.
2. India segment grew by 14.7% year-on-year driven by a 19.5% expansion in the chronic business and strong diabetes performance.
3. Other developed markets surged with 46% year-on-year growth while emerging markets declined 4% due to competition in Latin America.
4. Company guidance for US market run rate stands at least $1 billion plus for FY29 supported by biosimilar portfolio scaling.
5. EBITDA margins are expected to reach 29-30% over several quarters driven by secular growth from specialty products and biosimilars.
6. R&D spend increased to Rs 618 crore in Q2, accounting for 7.9% of sales as the company prioritizes complex injectables pipelines.
7. Management plans to launch approximately 20 products in FY27 with a focus on strategic growth in Europe and specialty areas.

⏱️ Chapters
0:00 Q1: What offsets gross margin decline after Tolvapton?
6:35 Q2: Will US FY28 revenues match or beat FY27?
9:15 Q3: What is the exit Tolvapton market share?
13:41 Q4: Is Apixaban strategy B2B or B2C focused?
18:33 Q5: Will Zyvav offer sole exclusivity in FY29?
20:47 Q6: What biosimilar launch learnings differ from small molecules?
26:08 Q7: Is Apexab addressable market 10 billion with attractive margins?
27:34 Q8: What is the timeline for peptide launches in US?
29:59 Q9: Will EBITDA margin reach 29-30% in five years?
32:55 Q10: Are you evaluating a partner for ApixaBand?

⚠️ Disclaimer: This video is for information and education only. It is not investment advice or a recommendation to buy, sell or hold any security, so please don't make buy or sell decisions based on it. The takeaways are prepared automatically from the call recording and some figures or numbers may contain errors. Always check them against the company's official filings before relying on them, and consult a SEBI-registered adviser before investing.

Company: Lupin Limited
Quarter: Q2 FY27
Call date: 4 November 2026

Concall Central: one stop place for concalls & management commentary.
👉 Subscribe so you never miss a concall. Like and share if this helped your research.

#Concall #EarningsCall #LUPIN #Q2FY27 #ConcallCentral #StockMarketIndia